Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Insights from 2023 ASCO® Annual Meeting
R

ASCO® 2023 Insights: "Epcoritamab + R² Regimen and Responses in High-Risk FL Regardless of POD24 Status"

By Insights from 2023 ASCO® Annual Meeting FEATURING Reid Merryman
June 27, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

15:18
Treatment Considerations in CLL: Challenging Patient Cases

Treatment Considerations for Ibrutinib-Intolerant Patients - A Patie…

Feat. M. Shadman

Featured Video

19:14
Bristol Myers Squibb Hematology

Study Results of a Treatment Option for AML Patients

Feat. J. Mccloskey, T. Leblanc
Lymphoma
12:43
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Bispecific Antibodies or CAR T-Cells for Indolent B-NHL?

Feat. C. Jacobson
05:36
Oncology Data Advisor

Phase 1/2 EPCORE NHL-2 Trial: Investigating Epcoritamab for R/R Foll…

Feat. R. Merryman
10:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Epcoritamab + R² Regimen and Responses in…

Feat. R. Merryman
19:42
Indy Hematology Review

Beyond Hyperviscosity: 80 Years and Counting - Treatment of Waldenst…

Feat. S. Treon
12:50
ASH 2022 Conference Coverage

ASH 2022 on Ibrutinib and Venetoclax in Previously Untreated Waldens…

Feat. J. Castillo
13:46
Dana-Farber Cancer Institute

Venetoclax in Previously Treated Waldenström Macroglobulinemia

Feat. J. Castillo